Evidence map›Paper›PMID 29671259›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2018

Genome-Edited Cell Lines for High-Throughput Screening.

Patricia Dranchak, John J Moran, Ryan MacArthur, Camila Lopez-Anido, James Inglese, John Svaren

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Patricia DranchakNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
John J MoranWaisman Center, University of Wisconsin, Madison, WI, USA.
Ryan MacArthurNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Camila Lopez-AnidoWaisman Center, University of Wisconsin, Madison, WI, USA.
James IngleseNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
John SvarenWaisman Center, University of Wisconsin, Madison, WI, USA. jpsvaren@wisc.edu.
University of Wisconsin–Madison · USNational Center for Advancing Translational Sciences · USNational Human Genome Research Institute · USNational Institutes of Health · US

Funding

Drug Screening Assays for Charcot-Marie-Tooth DiseaseR21NS073726 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI SVAREN, JOHN P · 2011 to 2012
$414k
NINDS NIH HHS R21 NS073726
6 · The paper itself

Abstract

Measurement of gene expression for high-throughput screening is an increasingly used technique that has been developed for not only gene dosage disorders resulting from disease-associated copy number variations, but also for induction/repression of genes modulating the severity of a disease phenotype. Traditional methods have employed transient or stable transfection of reporter constructs in which a single reporter is driven by selected regulatory elements from the candidate gene. However, individual regulatory elements are inherently unable to capture the integrated regulation of multiple enhancers at the endogenous locus, and random reporter insertion can result in neighborhood effects that impact the physiological responsiveness of the reporter. Therefore, we outline a general method of employing genome editing to insert reporters into the 3' UTR of a candidate gene, which has been used successfully in our studies of the Pmp22 gene associated with Charcot-Marie-Tooth disease. The method employs genome editing to insert two nonhomologous reporters that maximize the efficiency of identification of biologically active molecules through concordant responses in small molecule screening. We include a number of aspects of the design and construction of these reporter assays that will be applicable to creation of similar assays in a variety of cell types.

Indexed as

Biological AssayCell LineCharcot-Marie-Tooth DiseaseCRISPR-Cas SystemsGene EditingGenes, ReporterHigh-Throughput Screening AssaysHumansLuciferases, FireflyLuminescent MeasurementsMyelin ProteinsTransfectionLuciferases, FireflyMyelin ProteinsPMP22 protein, humanGene expressionGenomicsHTSRare diseaseReporter geneTranscription

Identifiers

PMID29671259
PMCPMC6362836
OpenAlexW2802958791

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.